Drug makers fighting back against advance of generics

Lewin, Tamar

doi:10.1093/ajhp/44.10.2189

American Journal of Health-System Pharmacy

1987

DOI: 10.1093/ajhp/44.10.2189

|View full text |Cite

Drug makers fighting back against advance of generics

Tamar Lewin¹

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1989

2010

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

What's in a Name? Generics and the Persistence of the Pharmaceutical Brand in American Medicine

Greene

2010

Journal of the History of Medicine and Allied Sciences

View full text Add to dashboard Cite

This paper explores the complex role that brand names have played in the maintenance of therapeutic standards within twentieth-century American medicine. What made a generic drug generic in the second half of the twentieth century--and by extension, what made a nonproprietary drug not proprietary in the first half--was dependent on changing drug branding practices and evolving standards of evidence attached to claims of therapeutic efficacy and safety. This article maps three eras of shifting oppositions between branded and unbranded pharmaceuticals. First, an era of "ethical marketing," extending from before the Pure Food and Drug Act of 1906 into roughly the 1930s, which pitted nonproprietary or "ethical" pharmaceuticals against proprietary or patent medicines; second, an era of ascendant brand-name prescribing from the 1930s until roughly the 1960s, as manufacturers of innovative and patent-protected "specialty" drugs depicted generic production as a form of counterfeiting; and finally, an era of generic backlash from the 1960s onwards, which assumed the interchangeability of branded and generic drugs. This article uses clinical, popular, policy, and trade literatures to explore the enduring roles of brand-logic in the face of generic competition in the American drug market.

show abstract

What's in a Name? Generics and the Persistence of the Pharmaceutical Brand in American Medicine

Greene

2010

Journal of the History of Medicine and Allied Sciences

View full text Add to dashboard Cite

show abstract

Pharmacists' Decision Making in the Selection of Generic Pharmaceuticals

Segal

1989

Journal of Pharmaceutical Marketing & Management

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Drug makers fighting back against advance of generics

Cited by 2 publications

References 0 publications

What's in a Name? Generics and the Persistence of the Pharmaceutical Brand in American Medicine

What's in a Name? Generics and the Persistence of the Pharmaceutical Brand in American Medicine

Pharmacists' Decision Making in the Selection of Generic Pharmaceuticals

Contact Info

Product

Resources

About